Monday, April 22, 2024
Advertisement
  1. You Are At:
  2. News
  3. India
  4. Bharat Biotech's nasal vaccine for Covid to cost Rs 800 for private hospitals, Rs 325 for governments

Bharat Biotech's nasal vaccine for Covid to cost Rs 800 for private hospitals, Rs 325 for governments

The nasal vaccine, iNCOVACC, which will be rolled out in the fourth week of January is for those above 18 years of age. The slots for the vaccine can now be booked on CoWin's portal.

Nivedita Dash Edited By: Nivedita Dash @Nivedita0503 New Delhi Updated on: December 27, 2022 13:11 IST
The vaccine is for those above 18 years of age.
Image Source : TWITTER The vaccine is for those above 18 years of age.

Nasal Vaccine: Bharat Biotech, one of Covid vaccine manufacturers, has announced the nasal vaccine costing for the public. One dose of the vasal vaccine will cost Rs 800 plus taxes at private hospitals and the Centre and the state governments can buy the nasal vaccine for Rs  325, Bharat Biotech has announced.

 The nasal vaccine, iNCOVACC, which will be rolled out in the fourth week of January is for those above 18 years of age. The slots for the vaccine can now be booked on CoWin's portal.

India Tv - iNCOVACC is the world’s first Intranasal vaccine for Covid to receive approval for the primary 2-dose schedule, and as a heterologous booster dose.

Image Source : INDIA TViNCOVACC is the world’s first Intranasal vaccine for Covid to receive approval for the primary 2-dose schedule, and as a heterologous booster dose.

iNCOVACC is the world’s first Intranasal vaccine for Covid to receive approval for the primary 2-dose schedule, and as a heterologous booster dose. Its phase III trials (as a 2-dose regimen) were conducted for safety, immunogenicity in 3100 subjects, in 14 trial sites across India.

Dr. Krishna Ella, Executive Chairman said; “We have achieved the goals we set for ourselves during this pandemic. We have developed COVAXIN and iNCOVACC , two Covid vaccines from two different platforms, with two different delivery systems. The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics. We thank the Ministry of Health, CDSCO, Dept of Biotechnology, Govt of India, Technology Development Board, and Washington University, St Louis, for their support and guidance.”

Advertisement

Read all the Breaking News Live on indiatvnews.com and Get Latest English News & Updates from India

Advertisement
Advertisement
Advertisement
Advertisement